Dexcom Continuous Glucose Monitoring in Long-term Care

Diabetes Mellitus, Type 2 Clinical Trial

Official title:

Randomized Controlled Trial To Assess the Benefits of Dexcom Continuous Glucose Monitoring With Glucose Telemetry System for the Management of Diabetes in Long-term Care Setting: The CGM-GTS in Long-term Care

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04818242
• Other study ID #: STUDY00001529
• Status: Completed
• Phase: N/A
• Start date: April 19, 2021
• Est. completion date: October 21, 2022

Study information

• Verified date: October 2023
• Source: Emory University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this study is to determine whether the use of Dexcom Continuous Glucose Monitoring with Glucose Telemetry System (CGM-GTS) with hypoglycemia alarm will facilitate diabetes treatment and reduce the risk of hypoglycemia in insulin and non-insulin treated patients with type 2 diabetes (T2D) in long-term care facilities, when compared to standard of care using capillary point of care testing.

Description:

The prevalence of diabetes increases with age, and it is estimated that more than 20% of older adults aged 65-75 years and 40% of adults over 80 years of age have diabetes. The prevalence of diabetes in older adults is expected to increase due to longer life expectancy and improvements in care. The estimated prevalence of diabetes in subacute and long-term skilled nursing care facilities is reported to be around 20% to 34% and, in parallel to the increasing geriatric population, the number of long-term care (LTC) admissions is expected to rise.

The goals of diabetes care in older adults and patients in subacute and long-term skilled nursing care facilities include control of hyperglycemia and its symptoms, prevention and treatment of diabetic complications, and maintenance or improvement of general health status. Studies in hospitalized patients with diabetes have shown that improvement in glucose control can reduce complications and are cost savings, however, no prospective studies have determined the impact of improving glucose control on clinical outcome in subacute and long-term skilled nursing care facilities. The management of diabetes in LTC residents is similar to that recommended for ambulatory patients with diabetes, however, several factors complicate the management of hyperglycemia in this population. LTC residents tend to be older and to have higher rates of comorbidities associated with aging such as functional disability, hypertension, coronary artery disease, cerebrovascular events, depression, cognitive impairment, urinary incontinence, and higher risk of falls. In addition, they often experience changes in nutritional intake, which increase the risk of hypoglycemia.

Current guidelines and position statements on diabetes management in older adults are based on consensus opinions or from extrapolations from studies involving middle-aged patients with diabetes. The American Diabetes Association guidelines recommend that older adults who are functional, cognitively intact, and have longer life expectancy should receive diabetes care with goals similar to those developed for younger adults. In these subjects, a HbA1c level <7.5%, a fasting glucose between 90-130 mg/dl, and a random glucose <180 mg/dl is recommended. Less intensive goals are recommended for patients with advanced complications, life-limiting comorbid illness, or cognitive impairment. Other organizations including the American Geriatric Society, European Diabetes Working Party for Older People guidelines, International Association of Gerontology and Geriatrics, the European Diabetes Working Party for Older People recommend a target HbA1c of <7.5% for patients without major comorbidities while a higher target of 7.6-8.5% is proposed for frail patients with high risk of hypoglycemia. These guidelines highlight the importance of improved glucose control and avoidance of side effects and hypoglycemia, as they are associated with increased risk of complications and mortality in patients with diabetes.

Bedside capillary point of care (POC) glucose monitoring is the standard of care to assess glycemic control in the hospital and in LTC facilities. POC testing is usually performed before meals and at bedtime. Continuous glucose monitoring (CGM) measures interstitial glucose every 5-15 minutes, thus providing a more complete glycemic profile during 24-hours than POC testing. This study is a randomized clinical trial to assess the impact of glucose control and hypoglycemia reduction with the use of real time CGM with an alarm system to prevent hypoglycemia and facilitate the care of insulin and non-insulin treated patients with T2D in subacute and long-term skilled nursing care facilities. The results of this study have great potential to impact and facilitate care and to change current clinical guidelines in the management of older adults with diabetes in subacute and LTC facilities.

Residents with T2D in subacute and long-term skilled nursing care facilities treated with insulin and/or insulin-secretagogues will be randomized to a standard of care group with POC testing or to real time Dexcom CGM with GTS until discharge or for up to 60 days of admission (whichever comes sooner). Participants in the standard of care group will wear a blinded CGM and receive POC testing before meals and bedtime, with providers adjusting oral agents or insulin dose based on POC results. Participants in the intervention CGM group will have a single daily fasting POC testing and will wear a real-time Dexcom G6 with GTS, and providers will adjust oral or insulin therapy based on CGM-GTS profile information.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: October 21, 2022
• Est. primary completion date: October 21, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Males and females admitted to subacute and long-term skilled nursing care facilities.

• Known history of T2D treated with insulin or insulin secretagogues with or without additional oral antidiabetic agents, short- and long-acting glucagon-like peptide-1 receptor agonists (GLP-1 RA).

• Patients with an expected long-term care facility length-of-stay > 1 week.

Exclusion Criteria:

• Patients expected to require MRI procedures during admission.

• Patients with clinically relevant hepatic disease (diagnosed liver cirrhosis and portal hypertension), corticosteroid therapy, end-stage renal disease (dialysis), or anasarca (massive peripheral edema).

• Female subjects who are pregnant or breast-feeding at time of enrollment into the study.

Related Conditions & MeSH terms

• Diabetes
• Diabetes Mellitus
• Diabetes Mellitus, Type 2

Intervention

Device:
• Dexcom G6 CGM with GTS
CGM sensor will be placed after consent. Glucose values obtained from the CGM sensor will be sent to the CGM transmitter by Bluetooth technology and Dexcom Share2 software application to a smart phone that serves as an intermediate-transmitting (routing) device. Glucose values from the smart phone will be transmitted wirelessly to a table computer (I-Pad) using the Dexcom Follow application. Information on the CGM will activate an alarm in case of hypoglycemia or hyperglycemia events. Hypoglycemia alarm will be set to < 85 mg/dl (for prevention for low blood glucose levels). Nursing staff will be instructed to provide 15 grams of carbohydrates in response to a hypoglycemia alarm.The hyperglycemia alarm will be set at 300 mg/dl. If this occurs, the nursing staff will assess clinical status and perform a POC glucose testing to confirm glucose values. If blood glucose (BG) > 300 mg/dl, nursing staff will communicate the high glucose value to the primary care team.

Diagnostic Test:
• POC Blood Glucose Test + Blinded CGM
Point of Care (POC) testing before meals and bedtime (standard of care). For the control group, participants will also get a CGM sensor (blinded CGM). CGM alarms are turned off, however if the POC is found to be between <80 mg/dl by POC, 15 grams of carbohydrates will be given as a preventive measurement for hypoglycemia (standard of care).

Locations

Country	Name	City	State
United States	A.G. Rhodes	Atlanta	Georgia
United States	Emory Wesley Woods Hospital	Atlanta	Georgia

Sponsors (2)

Lead Sponsor	Collaborator
Emory University	DexCom, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants Experiencing Hypoglycemia (BG<70 mg/dL)	The number of participants with hypoglycemia detected, where hypoglycemia is defined as blood glucose (BG) of less than 70 mg/dL.	During hospitalization (up to 60 days of admission)
Primary	Number of Participants Experiencing Clinically Significant Hypoglycemia (BG<54 mg/dL)	Clinically significant hypoglycemia is defined as blood glucose levels less than 54 mg/dL.	During hospitalization (up to 60 days of admission)
Primary	Time in Range (TIR) Between 70-180 mg/dL	Glycemic control is measured by time that blood glucose levels are in the range of 70 to 180 mg/dL.	During hospitalization (up to 60 days of admission)
Secondary	Number of Events of Nocturnal Hypoglycemia	The average number of events of nocturnal hypoglycemic events across all participants for BG < 70 mg/dL and <54 mg/dL occurring between 22:00 and 06:00.	During hospitalization (up to 60 days of admission)
Secondary	Number of Hypoglycemia Events	The total number of events of hypoglycemia events (BG <70 mg/dL and <54 mg/dL) across participants.	During hospitalization (up to 60 days of admission)
Secondary	Time in Hypoglycemia (BG<70 mg/dL)	The percent of time in hypoglycemia, defined as blood glucose level <70 mg/dL, is assessed.	During hospitalization (up to 60 days of admission)
Secondary	Percent of Time in Hypoglycemia (BG<54 mg/dL)	The percentage of time in hypoglycemia with blood glucose levels less than 54 mg/dL.	During hospitalization (up to 60 days of admission)
Secondary	Percent of Time in Hyperglycemia (BG > 180 mg/dL)	The percentage of time in hyperglycemia with blood glucose levels greater than 180 mg/dL.	During hospitalization (up to 60 days of admission)
Secondary	Percent of Time in Hyperglycemia (BG>250 mg/dL)	The percentage of time in hyperglycemia with blood glucose levels >250 mg/dL.	During hospitalization (up to 60 days of admission)
Secondary	Number of Events of Prolonged Hypoglycemia	The number of events of prolonged hypoglycemia, defined as > 1 and 2 hours, as determined by CGM.	During hospitalization (up to 60 days of admission)
Secondary	Number of Hypoglycemia Events During the Day and Night	The number of hypoglycemia events during the day and night in the POC testing group and the CGM-GTS group.	During hospitalization (up to 60 days of admission)
Secondary	Number of Events of Hyperglycemia > 180 mg/dL	Number of events of hyperglycemia > 180 mg/dL during the day and night between POC testing group and CGM-GTS group	During hospitalization (up to 60 days of admission)
Secondary	Number of Events of Hyperglycemia > 240 mg/dL	Number of events of hyperglycemia > 240 mg/dL during the day and night between POC testing group and CGM-GTS group	During hospitalization (up to 60 days of admission)
Secondary	Percentage of POC BG Readings Within Target BG of 70 and 180 mg/dL	The percentage of POC blood glucose readings within the target BG range of 70 and 180 mg/dL.	During hospitalization (up to 60 days of admission)
Secondary	Glycemic Variability Calculated by Mean Amplitude of Glycemic Excursions (MAGE)	Mean amplitude of glycemic excursions (MAGE), together with mean and standard deviation (SD), is the parameter for assessing glycemic variability and is calculated based on the arithmetic mean of differences between consecutive peaks and nadirs of differences greater than one SD of mean glycemia. It is designated to assess major glucose swings and exclude minor ones.	During hospitalization (up to 60 days of admission)
Secondary	Number of Participants With Problems With Sensor Insertion	The number of participants who experienced problems or issues while the sensor was being inserted was documented.	During hospitalization (up to 60 days of admission)